MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4

Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Autophagy 2020-04, Vol.16 (4), p.683-697
Hauptverfasser: Wu, Hongkun, Liu, Chang, Yang, Qingyuan, Xin, Chengde, Du, Juan, Sun, Fenyong, Zhou, Lin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 697
container_issue 4
container_start_page 683
container_title Autophagy
container_volume 16
creator Wu, Hongkun
Liu, Chang
Yang, Qingyuan
Xin, Chengde
Du, Juan
Sun, Fenyong
Zhou, Lin
description Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with the aberrant autophagy in various human cancers. However, to date, few miRNAs have been reported to directly modulate autophagy in the pathobiology of MM. In this study, we investigated the role of MIR145-3p (microRNA 145-3p) in MM, with focus on cellular processes autophagy and cell death. Our results provided evidence that downregulation of MIR145-3p expression was associated with disease progression in human MM. MIR145-3p triggered autophagic flux through direct targeting of HDAC4 (histone deacetylase 4) in MM cells, leading to enhanced apoptosis. Silencing HDAC4 recapitulated the effects of MIR145-3p, whereas enforced expression of HDAC4 abrogated the effects of MIR145-3p. Furthermore, we showed that suppression of HDAC4 by MIR145-3p resulted in upregulation of the pro-apoptotic protein BCL2L11 and caused MTORC1 inactivation, which in turn led to enhanced autophagy and cell death. Importantly, we demonstrated that MIR145-3p mimic could potentiate the anti-MM activity of bortezomib in both in vitro and in vivo experiments. Overall, our findings indicate that MIR145-3p exerted a tumor suppression function in MM by inducing autophagic cell death and suggest that MIR145-3p-based targeted therapy would represent a novel strategy for MM treatment. Abbreviations: 3-MA: 3-methyladenine; 3ʹ-UTR: 3ʹ-untranslated region; 7-AAD: 7-aminoactinomycin D; ACTB: actin beta; ANXA5: annexin A5; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; BAF: bafilomycin A 1 ; BCL2L11: BCL2 like 11; Bort: bortezomib; CASP3: caspase 3; CCK-8: Cell Counting Kit-8; CQ: chloroquine; Ct: threshold cycle; ctrl: control; DAPI: 4ʹ,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HDAC4: histone deacetylase 4; ISS: International Staging System; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; miRNAs: microRNAs; MIR145-3p: microRNA 145-3p; MM: multiple myeloma; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PCs: plasma cells; PFS: progression-free survival; qRT-PCR: quantitative reverse transcription PCR; RPS6KB1: ribo
doi_str_mv 10.1080/15548627.2019.1635380
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7138223</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2248379913</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-131a9738556079a3f5c2b6a45e05e34f8b976aa7d6ff8ad52b34e7df4cdb75c53</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhi0EoqXwE0A-csnijzh2LohqKbRSUaUKztYkcbJGsR1spyj8-ma12xVcONkeP_POSA9CbynZUKLIBypEqSomN4zQekMrLrgiz9D5vl6o9fn8dGfyDL1K6SchvFI1e4nOOGUlo6w-R8O3m3taioJPeIrBhWwShjmHaQfDgsF32Pgd-HYtNyFm8yc42-BkfLLZPti8YOuxm8dsp9Fgt5gxOMDNgjPEwWTrB3z9-XJbvkYvehiTeXM8L9CPL1fft9fF7d3Xm-3lbdFyXuWCcgq15EqIisgaeC9a1lRQCkOE4WWvmlpWALKr-l5BJ1jDSyO7vmy7RopW8Av08ZA7zY0zXWt8jjDqKVoHcdEBrP73x9udHsKDlpQrxvga8P4YEMOv2aSsnU2tGUfwJsxJM1YqLuua7lFxQNsYUoqmP42hRO8l6SdJei9JHyWtfe_-3vHU9WRlBT4dAOv7EB38DnHsdIZlDLGPqw2bVvi_Mx4B9dii0Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2248379913</pqid></control><display><type>article</type><title>MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wu, Hongkun ; Liu, Chang ; Yang, Qingyuan ; Xin, Chengde ; Du, Juan ; Sun, Fenyong ; Zhou, Lin</creator><creatorcontrib>Wu, Hongkun ; Liu, Chang ; Yang, Qingyuan ; Xin, Chengde ; Du, Juan ; Sun, Fenyong ; Zhou, Lin</creatorcontrib><description>Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with the aberrant autophagy in various human cancers. However, to date, few miRNAs have been reported to directly modulate autophagy in the pathobiology of MM. In this study, we investigated the role of MIR145-3p (microRNA 145-3p) in MM, with focus on cellular processes autophagy and cell death. Our results provided evidence that downregulation of MIR145-3p expression was associated with disease progression in human MM. MIR145-3p triggered autophagic flux through direct targeting of HDAC4 (histone deacetylase 4) in MM cells, leading to enhanced apoptosis. Silencing HDAC4 recapitulated the effects of MIR145-3p, whereas enforced expression of HDAC4 abrogated the effects of MIR145-3p. Furthermore, we showed that suppression of HDAC4 by MIR145-3p resulted in upregulation of the pro-apoptotic protein BCL2L11 and caused MTORC1 inactivation, which in turn led to enhanced autophagy and cell death. Importantly, we demonstrated that MIR145-3p mimic could potentiate the anti-MM activity of bortezomib in both in vitro and in vivo experiments. Overall, our findings indicate that MIR145-3p exerted a tumor suppression function in MM by inducing autophagic cell death and suggest that MIR145-3p-based targeted therapy would represent a novel strategy for MM treatment. Abbreviations: 3-MA: 3-methyladenine; 3ʹ-UTR: 3ʹ-untranslated region; 7-AAD: 7-aminoactinomycin D; ACTB: actin beta; ANXA5: annexin A5; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; BAF: bafilomycin A 1 ; BCL2L11: BCL2 like 11; Bort: bortezomib; CASP3: caspase 3; CCK-8: Cell Counting Kit-8; CQ: chloroquine; Ct: threshold cycle; ctrl: control; DAPI: 4ʹ,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HDAC4: histone deacetylase 4; ISS: International Staging System; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; miRNAs: microRNAs; MIR145-3p: microRNA 145-3p; MM: multiple myeloma; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PCs: plasma cells; PFS: progression-free survival; qRT-PCR: quantitative reverse transcription PCR; RPS6KB1: ribosomal protein S6 kinase B1; SD: standard deviation; siRNA: small interfering RNA; SQSTM1: sequestosome 1; STV: starvation; TUBB: tubulin beta class I.</description><identifier>ISSN: 1554-8627</identifier><identifier>EISSN: 1554-8635</identifier><identifier>DOI: 10.1080/15548627.2019.1635380</identifier><identifier>PMID: 31242129</identifier><language>eng</language><publisher>United States: Taylor &amp; Francis</publisher><subject>Animals ; Apoptosis ; Apoptosis - drug effects ; Apoptosis - genetics ; autophagic cell death ; autophagy ; Autophagy - drug effects ; Autophagy - physiology ; bortezomib ; Bortezomib - metabolism ; Bortezomib - pharmacology ; Down-Regulation - drug effects ; HDAC4 ; Histone Deacetylases - drug effects ; Histone Deacetylases - genetics ; Humans ; Lysosomes - drug effects ; Lysosomes - metabolism ; Mice ; MicroRNAs - drug effects ; MicroRNAs - genetics ; MIR145-3p ; multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - genetics ; Multiple Myeloma - pathology ; Repressor Proteins - drug effects ; Repressor Proteins - genetics ; Research Paper ; Up-Regulation - drug effects</subject><ispartof>Autophagy, 2020-04, Vol.16 (4), p.683-697</ispartof><rights>2019 Informa UK Limited, trading as Taylor &amp; Francis Group 2019</rights><rights>2019 Informa UK Limited, trading as Taylor &amp; Francis Group 2019 Informa UK Limited, trading as Taylor &amp; Francis Group</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-131a9738556079a3f5c2b6a45e05e34f8b976aa7d6ff8ad52b34e7df4cdb75c53</citedby><cites>FETCH-LOGICAL-c336t-131a9738556079a3f5c2b6a45e05e34f8b976aa7d6ff8ad52b34e7df4cdb75c53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138223/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7138223/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31242129$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Hongkun</creatorcontrib><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Yang, Qingyuan</creatorcontrib><creatorcontrib>Xin, Chengde</creatorcontrib><creatorcontrib>Du, Juan</creatorcontrib><creatorcontrib>Sun, Fenyong</creatorcontrib><creatorcontrib>Zhou, Lin</creatorcontrib><title>MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4</title><title>Autophagy</title><addtitle>Autophagy</addtitle><description>Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with the aberrant autophagy in various human cancers. However, to date, few miRNAs have been reported to directly modulate autophagy in the pathobiology of MM. In this study, we investigated the role of MIR145-3p (microRNA 145-3p) in MM, with focus on cellular processes autophagy and cell death. Our results provided evidence that downregulation of MIR145-3p expression was associated with disease progression in human MM. MIR145-3p triggered autophagic flux through direct targeting of HDAC4 (histone deacetylase 4) in MM cells, leading to enhanced apoptosis. Silencing HDAC4 recapitulated the effects of MIR145-3p, whereas enforced expression of HDAC4 abrogated the effects of MIR145-3p. Furthermore, we showed that suppression of HDAC4 by MIR145-3p resulted in upregulation of the pro-apoptotic protein BCL2L11 and caused MTORC1 inactivation, which in turn led to enhanced autophagy and cell death. Importantly, we demonstrated that MIR145-3p mimic could potentiate the anti-MM activity of bortezomib in both in vitro and in vivo experiments. Overall, our findings indicate that MIR145-3p exerted a tumor suppression function in MM by inducing autophagic cell death and suggest that MIR145-3p-based targeted therapy would represent a novel strategy for MM treatment. Abbreviations: 3-MA: 3-methyladenine; 3ʹ-UTR: 3ʹ-untranslated region; 7-AAD: 7-aminoactinomycin D; ACTB: actin beta; ANXA5: annexin A5; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; BAF: bafilomycin A 1 ; BCL2L11: BCL2 like 11; Bort: bortezomib; CASP3: caspase 3; CCK-8: Cell Counting Kit-8; CQ: chloroquine; Ct: threshold cycle; ctrl: control; DAPI: 4ʹ,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HDAC4: histone deacetylase 4; ISS: International Staging System; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; miRNAs: microRNAs; MIR145-3p: microRNA 145-3p; MM: multiple myeloma; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PCs: plasma cells; PFS: progression-free survival; qRT-PCR: quantitative reverse transcription PCR; RPS6KB1: ribosomal protein S6 kinase B1; SD: standard deviation; siRNA: small interfering RNA; SQSTM1: sequestosome 1; STV: starvation; TUBB: tubulin beta class I.</description><subject>Animals</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Apoptosis - genetics</subject><subject>autophagic cell death</subject><subject>autophagy</subject><subject>Autophagy - drug effects</subject><subject>Autophagy - physiology</subject><subject>bortezomib</subject><subject>Bortezomib - metabolism</subject><subject>Bortezomib - pharmacology</subject><subject>Down-Regulation - drug effects</subject><subject>HDAC4</subject><subject>Histone Deacetylases - drug effects</subject><subject>Histone Deacetylases - genetics</subject><subject>Humans</subject><subject>Lysosomes - drug effects</subject><subject>Lysosomes - metabolism</subject><subject>Mice</subject><subject>MicroRNAs - drug effects</subject><subject>MicroRNAs - genetics</subject><subject>MIR145-3p</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - genetics</subject><subject>Multiple Myeloma - pathology</subject><subject>Repressor Proteins - drug effects</subject><subject>Repressor Proteins - genetics</subject><subject>Research Paper</subject><subject>Up-Regulation - drug effects</subject><issn>1554-8627</issn><issn>1554-8635</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU1v1DAQhi0EoqXwE0A-csnijzh2LohqKbRSUaUKztYkcbJGsR1spyj8-ma12xVcONkeP_POSA9CbynZUKLIBypEqSomN4zQekMrLrgiz9D5vl6o9fn8dGfyDL1K6SchvFI1e4nOOGUlo6w-R8O3m3taioJPeIrBhWwShjmHaQfDgsF32Pgd-HYtNyFm8yc42-BkfLLZPti8YOuxm8dsp9Fgt5gxOMDNgjPEwWTrB3z9-XJbvkYvehiTeXM8L9CPL1fft9fF7d3Xm-3lbdFyXuWCcgq15EqIisgaeC9a1lRQCkOE4WWvmlpWALKr-l5BJ1jDSyO7vmy7RopW8Av08ZA7zY0zXWt8jjDqKVoHcdEBrP73x9udHsKDlpQrxvga8P4YEMOv2aSsnU2tGUfwJsxJM1YqLuua7lFxQNsYUoqmP42hRO8l6SdJei9JHyWtfe_-3vHU9WRlBT4dAOv7EB38DnHsdIZlDLGPqw2bVvi_Mx4B9dii0Q</recordid><startdate>20200402</startdate><enddate>20200402</enddate><creator>Wu, Hongkun</creator><creator>Liu, Chang</creator><creator>Yang, Qingyuan</creator><creator>Xin, Chengde</creator><creator>Du, Juan</creator><creator>Sun, Fenyong</creator><creator>Zhou, Lin</creator><general>Taylor &amp; Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200402</creationdate><title>MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4</title><author>Wu, Hongkun ; Liu, Chang ; Yang, Qingyuan ; Xin, Chengde ; Du, Juan ; Sun, Fenyong ; Zhou, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-131a9738556079a3f5c2b6a45e05e34f8b976aa7d6ff8ad52b34e7df4cdb75c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Apoptosis - genetics</topic><topic>autophagic cell death</topic><topic>autophagy</topic><topic>Autophagy - drug effects</topic><topic>Autophagy - physiology</topic><topic>bortezomib</topic><topic>Bortezomib - metabolism</topic><topic>Bortezomib - pharmacology</topic><topic>Down-Regulation - drug effects</topic><topic>HDAC4</topic><topic>Histone Deacetylases - drug effects</topic><topic>Histone Deacetylases - genetics</topic><topic>Humans</topic><topic>Lysosomes - drug effects</topic><topic>Lysosomes - metabolism</topic><topic>Mice</topic><topic>MicroRNAs - drug effects</topic><topic>MicroRNAs - genetics</topic><topic>MIR145-3p</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - genetics</topic><topic>Multiple Myeloma - pathology</topic><topic>Repressor Proteins - drug effects</topic><topic>Repressor Proteins - genetics</topic><topic>Research Paper</topic><topic>Up-Regulation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Hongkun</creatorcontrib><creatorcontrib>Liu, Chang</creatorcontrib><creatorcontrib>Yang, Qingyuan</creatorcontrib><creatorcontrib>Xin, Chengde</creatorcontrib><creatorcontrib>Du, Juan</creatorcontrib><creatorcontrib>Sun, Fenyong</creatorcontrib><creatorcontrib>Zhou, Lin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autophagy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Hongkun</au><au>Liu, Chang</au><au>Yang, Qingyuan</au><au>Xin, Chengde</au><au>Du, Juan</au><au>Sun, Fenyong</au><au>Zhou, Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4</atitle><jtitle>Autophagy</jtitle><addtitle>Autophagy</addtitle><date>2020-04-02</date><risdate>2020</risdate><volume>16</volume><issue>4</issue><spage>683</spage><epage>697</epage><pages>683-697</pages><issn>1554-8627</issn><eissn>1554-8635</eissn><abstract>Multiple myeloma (MM) is an incurable plasma cell malignancy with poor survival. Autophagy, a stress-responsive catabolic process mediated by lysosomal activity, plays a crucial role in the pathophysiology of MM. Growing evidence has indicated that dysregulated microRNAs (miRNAs) are associated with the aberrant autophagy in various human cancers. However, to date, few miRNAs have been reported to directly modulate autophagy in the pathobiology of MM. In this study, we investigated the role of MIR145-3p (microRNA 145-3p) in MM, with focus on cellular processes autophagy and cell death. Our results provided evidence that downregulation of MIR145-3p expression was associated with disease progression in human MM. MIR145-3p triggered autophagic flux through direct targeting of HDAC4 (histone deacetylase 4) in MM cells, leading to enhanced apoptosis. Silencing HDAC4 recapitulated the effects of MIR145-3p, whereas enforced expression of HDAC4 abrogated the effects of MIR145-3p. Furthermore, we showed that suppression of HDAC4 by MIR145-3p resulted in upregulation of the pro-apoptotic protein BCL2L11 and caused MTORC1 inactivation, which in turn led to enhanced autophagy and cell death. Importantly, we demonstrated that MIR145-3p mimic could potentiate the anti-MM activity of bortezomib in both in vitro and in vivo experiments. Overall, our findings indicate that MIR145-3p exerted a tumor suppression function in MM by inducing autophagic cell death and suggest that MIR145-3p-based targeted therapy would represent a novel strategy for MM treatment. Abbreviations: 3-MA: 3-methyladenine; 3ʹ-UTR: 3ʹ-untranslated region; 7-AAD: 7-aminoactinomycin D; ACTB: actin beta; ANXA5: annexin A5; ATG5: autophagy related 5; ATG7: autophagy related 7; B2M: beta-2-microglobulin; BAF: bafilomycin A 1 ; BCL2L11: BCL2 like 11; Bort: bortezomib; CASP3: caspase 3; CCK-8: Cell Counting Kit-8; CQ: chloroquine; Ct: threshold cycle; ctrl: control; DAPI: 4ʹ,6-diamidino-2-phenylindole; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GFP: green fluorescent protein; HDAC4: histone deacetylase 4; ISS: International Staging System; MAP1LC3B: microtubule associated protein 1 light chain 3 beta; miRNAs: microRNAs; MIR145-3p: microRNA 145-3p; MM: multiple myeloma; mRNA: messenger RNA; MTOR: mechanistic target of rapamycin kinase; MTORC1: mechanistic target of rapamycin kinase complex 1; PCs: plasma cells; PFS: progression-free survival; qRT-PCR: quantitative reverse transcription PCR; RPS6KB1: ribosomal protein S6 kinase B1; SD: standard deviation; siRNA: small interfering RNA; SQSTM1: sequestosome 1; STV: starvation; TUBB: tubulin beta class I.</abstract><cop>United States</cop><pub>Taylor &amp; Francis</pub><pmid>31242129</pmid><doi>10.1080/15548627.2019.1635380</doi><tpages>15</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1554-8627
ispartof Autophagy, 2020-04, Vol.16 (4), p.683-697
issn 1554-8627
1554-8635
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7138223
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Animals
Apoptosis
Apoptosis - drug effects
Apoptosis - genetics
autophagic cell death
autophagy
Autophagy - drug effects
Autophagy - physiology
bortezomib
Bortezomib - metabolism
Bortezomib - pharmacology
Down-Regulation - drug effects
HDAC4
Histone Deacetylases - drug effects
Histone Deacetylases - genetics
Humans
Lysosomes - drug effects
Lysosomes - metabolism
Mice
MicroRNAs - drug effects
MicroRNAs - genetics
MIR145-3p
multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - genetics
Multiple Myeloma - pathology
Repressor Proteins - drug effects
Repressor Proteins - genetics
Research Paper
Up-Regulation - drug effects
title MIR145-3p promotes autophagy and enhances bortezomib sensitivity in multiple myeloma by targeting HDAC4
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T14%3A50%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MIR145-3p%20promotes%20autophagy%20and%20enhances%20bortezomib%20sensitivity%20in%20multiple%20myeloma%20by%20targeting%20HDAC4&rft.jtitle=Autophagy&rft.au=Wu,%20Hongkun&rft.date=2020-04-02&rft.volume=16&rft.issue=4&rft.spage=683&rft.epage=697&rft.pages=683-697&rft.issn=1554-8627&rft.eissn=1554-8635&rft_id=info:doi/10.1080/15548627.2019.1635380&rft_dat=%3Cproquest_pubme%3E2248379913%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2248379913&rft_id=info:pmid/31242129&rfr_iscdi=true